On February 28, 2026, the National Medical Products Administration (NMPA) officially approved the marketing of JMKX001899 sulfate for the treatment of adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.
JMKX001899 is a highly selective KRAS G12C inhibitor and has previously received the “Breakthrough Therapy” designation from the NMPA.
Key clinical data are encouraging:
- The objective response rate (ORR) reached as high as 55.2%
- The 12-month overall survival (OS) rate reached 60.4%
In addition to the excellent survival benefit data, JMKX001899 also achieves significant optimization in the patient medication experience, adopting a convenient dosing regimen of “once daily, two tablets each time,” with good tolerability, thereby improving patient compliance with long-term medication.
Currently, clinical studies of this drug are also underway in patients with solid tumors such as colorectal cancer harboring KRAS G12C mutations, with the potential to benefit more types of cancer patients in the future.
**Why choose Beijing South Region Oncology Hospital International Department?**
- **Cutting-edge Medical Technology:** We stay abreast of the latest international advancements in oncology treatment and are among the first to introduce innovative drugs and therapies, including JMKX001899.
- **Multidisciplinary Expert Team:** Our multidisciplinary consultation team comprises experienced oncology specialists, radiologists, and pathologists who develop personalized treatment plans for each patient.
- **One-Stop Service:** From initial consultation and genetic testing to treatment plan development, medication guidance, and follow-up management, we provide seamless, end-to-end medical services.
- **International Treatment Environment:** Equipped with advanced medical facilities, we create a warm and comfortable healing environment and respect the specific needs of patients from diverse cultural backgrounds.
- **Language Support Services:** We offer multilingual translation services to eliminate communication barriers and ensure accurate communication between doctors and patients.
**Contact Us Now for Cutting-Edge Treatment Options**
If you or your loved one is facing the challenge of KRAS G12C-mutated advanced non-small cell lung cancer, please feel free to contact the International Department of Beijing South Region Oncology Hospital. Our professional team will provide you with detailed medical consultation and assistance for seeking medical care in China.
- Phone Consultation: 400-880-3716
- WeChat Consultation: 17801183037
- Email:
- 100085_010@163.com
- myimmnet@163.com
**Frequently Asked Questions**
**Q: How can international patients schedule medical services at the Beijing South Region Oncology Hospital International Department?**
**A:** You can contact us via phone, WeChat, or email. Our international patient coordinators will guide you through the appointment process, including medical record submission, remote consultation arrangement, and visa assistance for traveling to China.
**Q: What are the costs for international patients receiving treatment in China?**
**A:** Treatment costs vary depending on individual circumstances, including the medication regimen and treatment duration. After contacting us, we will provide a detailed cost estimate based on your specific situation.
**Q: Does the hospital offer remote consultation services?**
**A:** Yes, we provide remote video consultation services for international patients, allowing you to have a preliminary discussion with our expert team before traveling to China to understand the treatment plan and expected outcomes.
Post time: Mar-04-2026